Venclexta safety warnings in multiple myeloma patients
US regulators have posted a safety statement warning of an increased risk of death for patients receiving AbbVie’s venetoclax with bortezomib and dexamethasone for melanoma patients.
Read More
Tag: bortezomib
NICE turns down Darzalex combo for pre-treated multiple myeloma
Janssen says it is disappointed that NHS cost regulators are not backing NHS use of Darzalez (daratumumab) plus bortezomib and dexamethasone (DBd) for previously treated multiple myeloma in adults.
Read More
Data show Imnovid-based triple therapy PFS benefit in blood cancer
Celgene has presented Phase III data showing a significant progression-free survival (PFS) benefit in patients with multiple myeloma taking a triple combination therapy of Imnovid, Velcade and low-dose dexamethasone.
Read More
NICE rejects earlier use of multiple myeloma drugs
Patients with multiple myeloma are being barred from routine access on the NHS to Celgene’s Revlimid and Amgen’s Kyprolis in the second-line setting.
Read More
Six medicines win backing for EU approval
Six medicines, including two new combination therapies for chronic hepatitis C, are lining up for EU approval after having been recommended by the European Medicines Agency’s Committee for Medicinal Products for Human Use.
Read More
- HUTCHMED begins global trial of novel attc therapy hmpl‑a580 in solid tumours
- Theolytics awarded €8 million Horizon Europe grant to fund ovarian cancer study
- AI system aims to uncover Alzheimer’s earlier and take on diagnostic delays
- Quell launches chill phase 1/2 trial for novel cartreg therapy
- Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M
